US EditionPublished • loading... • Updated
Five takeaways after Merck's $9.2B Cidara deal: More M&A, 'diversified' growth, shifting production to the US
Summary by endpoints.news
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
Five takeaways after Merck's $9.2B Cidara deal: More M&A, 'diversified' growth, shifting production to the US
It appears $19 billion in deals this year is just the beginning of Merck's plan to build its next chapter. Merck has the world's top-selling medicine, but it will need a suite of treatments to ...
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
